In CLL, malignant B cells exhibit alterations that make them resistant to this form of cell death (e.g., ATM/P53 inactivation or over-expression of the anti-apoptotic proteins MCL1 or BCL2). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.